UK markets closed

Dynavax Technologies Corporation (DVAX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
11.28-0.06 (-0.53%)
At close: 04:00PM EDT
11.17 -0.11 (-0.98%)
After hours: 07:32PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close11.34
Open11.38
Bid0.00 x 0
Ask0.00 x 0
Day's range11.18 - 11.45
52-week range10.48 - 15.15
Volume1,503,576
Avg. volume1,962,576
Market cap1.476B
Beta (5Y monthly)1.19
PE ratio (TTM)161.14
EPS (TTM)0.07
Earnings date01 Aug 2024 - 05 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est25.75
  • PR Newswire

    Dynavax to Present at Upcoming Investor Conferences

    Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the following upcoming investor conferences during the month of June:

  • Reuters

    UPDATE 1-US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine

    Dynavax Technologies said on Tuesday the U.S. Food and Drug Administration (FDA) has declined to approve the expanded use of its hepatitis B vaccine in patients undergoing hemodialysis, citing insufficient safety and effectiveness data. The FDA, in its so-called "complete response letter", stated that the data was insufficient as a third-party clinical trial site operator had destroyed data source documents for about half of the subjects enrolled in the vaccine's trial, according to the company. Dynavax's vaccine, Heplisav-B, was first approved by the FDA in 2017, having been rejected twice before in 2013 and 2016 over unresolved safety concerns.

  • PR Newswire

    Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S.

    Dynavax Technologies Corporation (Nasdaq: DVAX) today provided a regulatory update for the Company's supplemental Biologics License Application (sBLA) to include a four-dose HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted] regimen for adults on hemodialysis. The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) in response to the sBLA, stating that the application did not provide sufficient data to support the full evaluation of effectiveness